Overview

Human growth hormone (HGH), also known as somatotropin, is a 191-amino acid single-chain polypeptide secreted by somatotroph cells in the anterior pituitary gland. It plays a central role in linear growth during childhood and continues to regulate critical metabolic processes throughout life, including body composition, lipid metabolism, bone density, muscle protein synthesis, and cellular regeneration. HGH exerts its effects both directly and through stimulation of insulin-like growth factor 1 (IGF-1) produced primarily in the liver, forming the GH–IGF-1 axis that governs much of its anabolic and reparative activity.

Recombinant HGH (rhGH) is FDA-approved for growth hormone deficiency (GHD) in children and adults, Turner syndrome, chronic kidney disease, Prader-Willi syndrome, and HIV-associated wasting. In adult GHD, replacement therapy consistently improves body composition (reducing visceral fat and increasing lean mass), bone mineral density, exercise capacity, and quality of life. Its mechanism involves activation of the JAK2-STAT5 signaling pathway, upregulation of hepatic IGF-1, and direct lipolytic effects through hormone-sensitive lipase activation. These properties have made HGH a subject of intense interest in anti-aging medicine, though off-label use remains controversial due to potential side effects including insulin resistance, fluid retention, and theoretical oncogenic risk.

The growth hormone secretagogue field has expanded significantly with peptides like sermorelin, ipamorelin, CJC-1295, and tesamorelin that stimulate endogenous GH release rather than replacing it directly. These alternatives offer a more physiological pulsatile release pattern and a generally improved safety profile. MK-677 (ibutamoren), an oral GH secretagogue, provides another approach to augmenting the GH–IGF-1 axis. Understanding the distinctions between exogenous HGH and these secretagogues is essential for clinicians designing protocols for age-related decline, recovery, or body composition optimization.

Mechanism of Action

Growth Hormone Receptor Activation & JAK-STAT Signaling

Human growth hormone (HGH, somatotropin) is a 191-amino acid peptide hormone secreted by somatotroph cells of the anterior pituitary. It binds to the growth hormone receptor (GHR), a single-pass transmembrane receptor of the cytokine receptor superfamily. HGH binding induces GHR dimerization and a conformational change that activates the receptor-associated Janus kinase 2 (JAK2) through transphosphorylation. Activated JAK2 phosphorylates tyrosine residues on the GHR intracellular domain, creating docking sites for STAT5a/5b (signal transducer and activator of transcription). Phosphorylated STAT5 dimerizes, translocates to the nucleus, and activates transcription of target genes, most importantly insulin-like growth factor 1 (IGF-1) (PMID: 12954753).

IGF-1 Axis — Endocrine & Paracrine Growth Signaling

Hepatic IGF-1, produced in response to GH-STAT5 signaling, mediates many of GH's systemic growth-promoting effects. IGF-1 binds the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase that activates the PI3K/Akt/mTOR pathway (promoting protein synthesis, cell growth, and survival) and the Ras/MAPK/ERK pathway (stimulating cell proliferation and differentiation). Locally produced IGF-1 also acts in a paracrine/autocrine manner in bone, muscle, and cartilage (PMID: 11138379).

Direct Metabolic Actions

Independent of IGF-1, GH exerts direct metabolic effects via JAK2 signaling: it stimulates lipolysis in adipocytes by activating hormone-sensitive lipase (HSL) and suppressing lipoprotein lipase (LPL); it promotes gluconeogenesis and reduces peripheral glucose uptake (counter-regulatory to insulin); and it enhances amino acid uptake and protein synthesis in skeletal muscle via mTOR activation (PMID: 10484055).

Bone & Cartilage — Growth Plate Effects

At the epiphyseal growth plate, GH stimulates prechondrocyte differentiation directly, while IGF-1 drives clonal expansion of chondrocytes. This dual action — direct GH priming plus IGF-1-mediated proliferation — underlies longitudinal bone growth. GH also stimulates osteoblast activity and bone remodeling through both STAT5 and local IGF-1 production.

Reconstitution Calculator

Safety Profile

Safety Profile: HGH (Human Growth Hormone / Somatropin)

Common Side Effects

• Peripheral edema (fluid retention, swelling in hands, feet, and ankles)
• Joint pain (arthralgia) and muscle pain (myalgia)
• Carpal tunnel syndrome (numbness, tingling in hands)
• Headache
• Elevated blood glucose and insulin resistance
• Injection site reactions (redness, pain, lipodystrophy)
• Mild gynecomastia
• Morning stiffness and paresthesias

Serious Adverse Effects

• Diabetes mellitus: HGH induces insulin resistance; may precipitate type 2 diabetes in predisposed individuals or worsen existing diabetes
• Carcinogenesis risk: Elevated IGF-1 levels are associated with increased risk of colorectal, prostate, and breast cancers; HGH is contraindicated with active malignancy
• Intracranial hypertension (pseudotumor cerebri): Particularly in pediatric patients; presents with headache, visual changes, papilledema
• Cardiomegaly and cardiomyopathy: Chronic supraphysiologic doses can cause pathological cardiac hypertrophy
• Slipped capital femoral epiphysis: In growing children; presents as hip or knee pain and limping
• Scoliosis progression: May accelerate in rapidly growing children
• Pancreatitis: Rare but documented; higher risk in children
• Hypothyroidism: HGH increases T4-to-T3 conversion and may unmask central hypothyroidism

Contraindications

• Active malignancy of any type
• Active proliferative or severe non-proliferative diabetic retinopathy
• Acute critical illness (increased mortality demonstrated in ICU patients on HGH)
• Closed epiphyses with intent to increase height (ineffective and risky)
• Known hypersensitivity to somatropin or excipients
• Active Prader-Willi syndrome with severe obesity or respiratory impairment (risk of sudden death)

Drug Interactions

• Insulin and oral hypoglycemics: HGH antagonizes insulin action; dose adjustments of diabetes medications are frequently required
• Corticosteroids: May attenuate HGH response; concomitant use requires monitoring of both axes
• Thyroid hormones: HGH may unmask hypothyroidism; monitor TSH and free T4
• CYP450 substrates: HGH may induce CYP3A4 and affect metabolism of drugs like cyclosporine, sex steroids, and anticonvulsants
• Estrogen (oral): Oral estrogen reduces IGF-1 response to HGH; transdermal estrogen has less impact
• Anticoagulants: May require dose adjustment; monitor INR

Population-Specific Considerations

• Pediatric: FDA-approved for multiple conditions (GHD, Turner syndrome, SGA, PWS, ISS); requires close monitoring for intracranial hypertension, SCFE, and scoliosis
• Elderly: Lower starting doses recommended; higher sensitivity to side effects including edema and glucose intolerance
• Cancer survivors: Generally requires 2+ years of cancer remission before initiating HGH therapy; lifelong cancer surveillance recommended
• Diabetics: HGH worsens glycemic control; frequent glucose monitoring and medication adjustment essential
• Pregnancy/Lactation: Category B/C depending on formulation; use only if clearly needed
• Athletes: Banned by WADA; exogenous HGH is detectable via biomarker testing

Pharmacokinetic Profile